CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 13.4% in December

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 4,800,000 shares, a decrease of 13.4% from the December 15th total of 5,540,000 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is presently 3.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $5.77.

Hedge Funds Weigh In On CytomX Therapeutics

Large investors have recently made changes to their positions in the business. Traphagen Investment Advisors LLC purchased a new stake in CytomX Therapeutics during the 4th quarter worth approximately $31,000. US Bancorp DE acquired a new position in shares of CytomX Therapeutics in the 3rd quarter valued at $40,000. XTX Topco Ltd raised its stake in CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 48,033 shares during the last quarter. Forefront Analytics LLC increased its holdings in shares of CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 43,176 shares during the period. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares during the period. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Performance

NASDAQ:CTMX traded down $0.01 during trading hours on Friday, reaching $0.84. The company’s stock had a trading volume of 620,234 shares, compared to its average volume of 992,394. The company has a market capitalization of $65.74 million, a P/E ratio of 4.94 and a beta of 1.03. The stock has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.15. CytomX Therapeutics has a 12 month low of $0.79 and a 12 month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. During the same period in the previous year, the company posted $0.04 earnings per share. As a group, analysts predict that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.